<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111643">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650545</url>
  </required_header>
  <id_info>
    <org_study_id>AI001</org_study_id>
    <nct_id>NCT01650545</nct_id>
  </id_info>
  <brief_title>Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients</brief_title>
  <official_title>A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center pilot study to investigate the efficacy and safety of aerosolized
      liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients
      with bronchiolitis obliterans syndrome (BOS).

      The primary objective is to evaluate the efficacy of liposomal cyclosporine A in the
      treatment of chronic rejection. Pulmonary function and changes in BOS grade are the primary
      end points.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized single-center pilot study to investigate the efficacy and safety of
      aerosolized liposomal cyclosporine A (L-CsA) in the treatment of chronic rejection in lung
      transplant recipients with Grade 1 or 2 BOS.

      The primary endpoints will include:

        -  Improvement or stabilization of pulmonary function test (FEV1) from baseline

        -  Stabilization of histology (no deterioration from baseline)

        -  Safety of the preparation

      The secondary endpoints will include:

        -  Pharmacokinetics and distribution of CsA in blood -

        -  Change in cytokine levels from BAL specimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung Function</measure>
    <time_frame>2 years</time_frame>
    <description>Preservation of lung function is an indication of overall health of the lung allograft</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine analysis from BAL fluid in lung</measure>
    <time_frame>2 years</time_frame>
    <description>This is a surrogate marker of lung inflammation that may be used in addition to biopsy data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Disorder Related to Lung Transplantation</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Decreased Immunologic Activity</condition>
  <condition>Chronic Rejection of Lung Transplant</condition>
  <arm_group>
    <arm_group_label>liposomal aerosol cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aerosol liposomal cyclosporine inhalational therapy for 6 months at two doses to be defined by transplant type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional immune suppression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard immune suppression oral for lung transplant recipients tacrolimus, mycophenolate mofetil and prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal aerosol cyclosporine</intervention_name>
    <description>inhaled form of immune suppression</description>
    <arm_group_label>liposomal aerosol cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard immune suppression, oral</intervention_name>
    <description>conventional drug</description>
    <arm_group_label>conventional immune suppression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Chronic rejection

          1. Bronchiolitis obliterans diagnosed by bronchiolitis obliterans syndrome and &gt; 20%
             decline from the individual patient's best FEV1 is observed

          2. Recipient of a double or single lung transplant

          3. Receiving immunosuppressive treatment according to institutional standards

        Exclusion criteria:

          1. Active invasive bacterial, viral or fungal infection

          2. Current mechanical ventilation

          3. Pregnant or breast-feeding woman

          4. Known hypersensitivity to cyclosporine A

          5. Serum creatinine value of more than 265 Î¼mol/L (3 mg/dL) or chronic dialysis

          6. Receipt of an investigational drug as part of a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo T Iacono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006 Jan 12;354(2):141-50.</citation>
    <PMID>16407509</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 21, 2015</lastchanged_date>
  <firstreceived_date>June 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Aldo Iacono</investigator_full_name>
    <investigator_title>Professor of Medicine Medical Director of Lung Transplantation</investigator_title>
  </responsible_party>
  <keyword>case-control study</keyword>
  <keyword>aerosolized liposomal cyclosporine A</keyword>
  <keyword>bronchiolitis obliterans syndrome</keyword>
  <keyword>Lung Transplantation</keyword>
  <keyword>Lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
